2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1754

Childhood- Vs. Adult-Onset ANCA-Associated Vasculitides: A Nested, Matched Case–Control Study from the French Vasculitis Study Group Registry
Abstract Number: 1755

Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis
Abstract Number: 1756

Interstitial Lung Disease in ANCA Associated Vasculitis: A Distinct or an Incomplete Subset in ANCA Vasculitis Patients?
Abstract Number: 1757

Rituximab for Induction and Maintenance Therapy of Granulomatosis with Polyangiitis: A Single-Center Cohort Study on 114 Patients
Abstract Number: 1758

Risk of Serious Infection in Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of 126 Wegent Trial Patients
Abstract Number: 1759

Economic Evaluation of Rituximab Versus Azathioprine for Maintenance Treatment of ANCA-Associated Vasculitis. a Prospective, Multicenter Study
Abstract Number: 1760

Pulmonary Manifestations in Microscopic Polyangiitis and Granulomatosis with Polyangiitis: A Multicenter Cohort Analysis
Abstract Number: 1761

Differential Characteristics of MPO-ANCA Positive and Negative Eosinophilic Granulomatosis with Polyangiitis
Abstract Number: 1762

Association of ETS1 Polymorphism in 3’ Untranslated Region with Susceptibility to Granulomatosis with Polyangiitis and Proteinase 3-ANCA Positive Vasculitis in a Japanese Population
Abstract Number: 1763

Time to Diagnosis of ANCA-Associated Vasculitides : Data from French Vasculitis Study Group Registry
Abstract Number: 1764

Small RNA Sequencing Shows Differential Plasma Microrna Expression in Patients with ANCA-Associated Vasculitis: A Pilot Study
Abstract Number: 1765

Validation of the ACR EULAR Provisional 2017 Classification Criteria of Granulomatosis with Polyangiitis (GPA) Amongst Patients with ANCA Associated Vasculitis
Abstract Number: 1766

Increased Renal Damage in Hypocomplementemic Patients with ANCA- Associated Vasculitis
Abstract Number: 1767

The Effect on Health-Related Quality of Life of Treatment for Remission Maintenance in ANCA-Associated Vasculitis Beyond 18 Months
Abstract Number: 1768

Cocaine and ANCA Associated Vasculitis-like Syndromes – a Case Series

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].